Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD

Diabetes, obesity & metabolism1 Jul 2006Cited by 154 (Europe PMC)

PMID16776749DOI10.1111/j.1463-1326.2006.00589.xPepBankPUB-16776749

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced HbA1c by 1.3% from baseline at week 82.
In plain wordsExenatide lowered HbA1c by 1.3% from baseline at week 82.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change at week 82
Study
n = 92
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Measurements
HbA1c change
−1.3%
week 82
Source sentences
Summary
At the end of the placebo-controlled trial, exenatide resulted in an haemoglobin A1c (HbA1c) reduction from baseline of -1.0 +/- 0.1% (mean +/- SE) (exenatide treatment arms), with durable HbA1c reductions after 82 weeks of -1.3 +/- 0.1%.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674902
02HumanNon-randomized trialEfficacy outcome
At week 82, 59% of exenatide-treated patients achieved HbA1c at or below 7%.
In plain wordsAt week 82, 59% of exenatide-treated patients reached HbA1c of 7% or less.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHbA1c target at week 82
Study
n = 92
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Measurements
Patients reaching HbA1c <=7%
59%
week 82
Source sentences
Summary
The percent of patients who achieved HbA1c < or = 7% at weeks 30 and 82 was 46 and 59% respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674904
03HumanNon-randomized trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced weight by 5.3 kg from baseline at week 82.
In plain wordsExenatide lowered weight by 5.3 kg from baseline at week 82.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change at week 82
Study
n = 92
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Measurements
Weight change from baseline at week 82
−5.3 kg
completer cohort, week 82
Source sentences
Summary
After 30 weeks, exenatide caused a reduction in weight from baseline of -3.0 +/- 0.6 kg, with a progressive reduction in weight of -5.3 +/- 0.8 kg after 82 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674906
04HumanNon-randomized trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide improved unspecified cardiovascular risk factors after 82 weeks.
In plain wordsExenatide improved unspecified heart and blood vessel risk factors after 82 weeks.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableCardiovascular risk factors
Study
n = 92
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Source sentences
Summary
In addition, exenatide treatment produced clinically significant improvements in cardiovascular risk factors after 82 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674907
05HumanNon-randomized trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced HbA1c by 1.0% from baseline at week 30.
In plain wordsExenatide lowered HbA1c by 1.0% from baseline at week 30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change at week 30
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
HbA1c change
−1%
exenatide arms at week 30
Source sentences
Summary
At the end of the placebo-controlled trial, exenatide resulted in an haemoglobin A1c (HbA1c) reduction from baseline of -1.0 +/- 0.1% (mean +/- SE) (exenatide treatment arms), with durable HbA1c reductions after 82 weeks of -1.3 +/- 0.1%.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674901
06HumanNon-randomized trialEfficacy outcome
At week 30, 46% of exenatide-treated patients achieved HbA1c at or below 7%.
In plain wordsAt week 30, 46% of exenatide-treated patients reached HbA1c of 7% or less.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHbA1c target at week 30
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Patients reaching HbA1c <=7%
46%
week 30
Source sentences
Summary
The percent of patients who achieved HbA1c < or = 7% at weeks 30 and 82 was 46 and 59% respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674903
07HumanNon-randomized trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced weight by 3.0 kg from baseline at week 30.
In plain wordsExenatide lowered weight by 3.0 kg from baseline at week 30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change at week 30
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Weight change
−3 kg
week 30
Source sentences
Summary
After 30 weeks, exenatide caused a reduction in weight from baseline of -3.0 +/- 0.6 kg, with a progressive reduction in weight of -5.3 +/- 0.8 kg after 82 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674905
08HumanNon-randomized trialSafety outcome
Nausea was the most frequent adverse event after 30 and 82 weeks of exenatide and was generally mild or moderate.
In plain wordsNausea was the most frequent side effect after 30 and 82 weeks of exenatide, generally mild or moderate.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Source sentences
Summary
The most frequent adverse event after 30 and 82 weeks of exenatide was nausea, which was generally of mild-or-moderate intensity.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674908
09HumanNon-randomized trialSafety outcome
During exenatide treatment, nausea incidence decreased after initiation in the controlled trial and uncontrolled extension.
In plain wordsNausea became less common after exenatide initiation in the trial and extension.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea incidence over time
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Source sentences
Summary
It decreased in incidence after initiation in the controlled trial and the uncontrolled open-label extension.
4 context sentences(design, population, supporting numbers)
Summary · context
The most frequent adverse event after 30 and 82 weeks of exenatide was nausea, which was generally of mild-or-moderate intensity.
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674909
10HumanNon-randomized trialSafety outcome
Hypoglycaemia was rare during exenatide treatment in metformin-treated patients with type 2 diabetes.
In plain wordsLow blood sugar was rare during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Source sentences
Summary
Hypoglycaemia was rare, with no severe events.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674910
11HumanNon-randomized trialSafety outcome
No severe hypoglycaemic events occurred during exenatide treatment in metformin-treated patients with type 2 diabetes.
In plain wordsNo severe low blood sugar events occurred during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSevere hypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 82 weeksAs given in this study (human).
Source sentences
Summary
Hypoglycaemia was rare, with no severe events.
3 context sentences(design, population, supporting numbers)
Summary · context
In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open-label extension of a 30-week double-blind, placebo-controlled trial.
Summary · context
Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy.
Summary · context
Patients continued metformin throughout the study.
Report a problemFND-1677674911

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00039013

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

AstraZenecan = 336Mar 2002 to Jun 2003

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 24 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.